| Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia JC Byrd, JR Brown, S O'Brien, JC Barrientos, NE Kay, NM Reddy, ... New England Journal of Medicine 371 (3), 213-223, 2014 | 1926 | 2014 |
| Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia V Quesada, L Conde, N Villamor, GR Ordóñez, P Jares, L Bassaganyas, ... Nature Genetics 44 (1), 47-52, 2012 | 1241 | 2012 |
| Non-coding recurrent mutations in chronic lymphocytic leukaemia XS Puente, S Beà, R Valdés-Mas, N Villamor, J Gutiérrez-Abril, ... Nature 526 (7574), 519-524, 2015 | 989 | 2015 |
| Acquired haemophilia: review and meta‐analysis focused on therapy and prognostic factors J Delgado, V Jimenez‐Yuste, F Hernandez‐Navarro, A Villar British Journal of Haematology 121 (1), 21-35, 2003 | 627 | 2003 |
| Recurrent mutations refine prognosis in chronic lymphocytic leukemia P Baliakas, A Hadzidimitriou, LA Sutton, D Rossi, E Minga, N Villamor, ... Leukemia 29 (2), 329-336, 2015 | 384 | 2015 |
| Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1 and ATM mutations in chronic lymphocytic leukemia F Nadeu, J Delgado, C Royo, T Baumann, T Stankovic, M Pinyol, P Jares, ... Blood 127 (17), 2122-2230, 2016 | 367 | 2016 |
| The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL IW Flinn, P Hillmen, M Montillo, Z Nagy, Á Illés, G Etienne, J Delgado, ... Blood 132 (23), 2446-2455, 2018 | 345 | 2018 |
| A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European … AC Rawstron, C Fazi, A Agathangelidis, N Villamor, R Letestu, ... Leukemia 30 (4), 929-936, 2016 | 265 | 2016 |
| Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL JR Brown, P Hillmen, S O’brien, JC Barrientos, NM Reddy, SE Coutre, ... Leukemia 32 (1), 83-91, 2018 | 262 | 2018 |
| COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus L Scarfò, T Chatzikonstantinou, GM Rigolin, G Quaresmini, M Motta, ... Leukemia 34 (9), 2354-2363, 2020 | 260 | 2020 |
| Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed/refractory CLL: interim results of a phase 3, randomised, double-blind, placebo … AD Zelenetz, JC Barrientos, JR Brown, B Coiffier, J Delgado, M Egyed, ... The Lancet Oncology 18 (3), 297-311, 2017 | 259* | 2017 |
| Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia RJ Kreitman, C Dearden, PL Zinzani, J Delgado, L Karlin, T Robak, ... Leukemia 32 (8), 1768-1777, 2018 | 255 | 2018 |
| NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome N Villamor, L Conde, A Martínez-Trillos, M Cazorla, A Navarro, S Bea, ... Leukemia 27 (5), 1100-1106, 2013 | 242 | 2013 |
| Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact P Baliakas, S Jeromin, M Iskas, A Puiggros, K Plevova, F Nguyen-Khac, ... Blood 133 (11), 1205-1216, 2019 | 239 | 2019 |
| The reference epigenome and regulatory chromatin landscape of chronic lymphocytic leukemia R Beekman, V Chapaprieta, N Russiñol, R Vilarrasa-Blasi, ... Nature Medicine 24 (6), 868-80, 2018 | 186 | 2018 |
| Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study J Delgado, K Thomson, N Russell, J Ewing, W Stewart, G Cook, ... Blood 107 (4), 1724-1730, 2006 | 186 | 2006 |
| Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome A Martínez-Trillos, M Pinyol, A Navarro, M Aymerich, P Jares, M Juan, ... Blood 123 (24), 3790-3796, 2014 | 170 | 2014 |
| A B-cell epigenetic signature defines three biologic subgroups of chronic lymphocytic leukemia with clinical impact AC Queirós, N Villamor, G Clot, A Martinez-Trillos, M Kulis, A Navarro, ... Leukemia 29 (3), 598-605, 2015 | 167 | 2015 |
| Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data RF Duarte, BE Shaw, P Marín, P Kottaridis, M Ortiz, C Morante, J Delgado, ... Bone Marrow Transplantation 46 (1), 52, 2011 | 156 | 2011 |
| Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia F Bosch, P Abrisqueta, N Villamor, MJ Terol, E González-Barca, C Ferra, ... Journal of Clinical Oncology 27 (27), 4578-4584, 2009 | 154 | 2009 |
Neus VillamorHospital ClinicPatvirtintas el. paštas clinic.cat
